Skip to main content
. 2024 Sep 2;10(17):e37287. doi: 10.1016/j.heliyon.2024.e37287

Table 1.

Gender-wise characteristics and infection as well as vaccination status of the subjects.

Variable Male,
N = 108 (n%)
Female,
N = 159 (n%)
Total,
N = 267 (n%)
p-value (Male vs Female)
Age, year, Median (Range) 45 (25–60) 35 (21–65) 38 (21–65) 0.01
Age <40 years 51 (47.2 %) 93 (58.5 %) 144 (53.9 %) 0.21
Age 40–50 years 21 (19.4 %) 27 (17 %) 48 (18 %)
Age >50 years 36 (33.3 %) 39 (24.5) 75 (28.1 %)
BMI, kg/m2, Median (Range) 25 (15–49) 25 (15–41) 25 (15–49) 0.823
Low, BMI <18.5 5 (4.6 %) 16 (10.1 %) 21 (7.9 %) 0.001
Ideal, BMI 18.5–22.9 13 (12 %) 45 (28.3 %) 58 (21.7 %)
Overweight, BMI 23.0–27.5 50 (46.3 %) 62 (39 %) 112 (41.9 %)
Obese, BMI >27.5 40 (37.0 %) 36 (22.6 %) 76 (28.5 %)
WHR, Median (Range) 0.92 (0.68–1.21) 0.91 (0.46–1.08) 0.92 (0.46–1.21) <0.001
Low WHR (<0.95, M; <0.80, F) 61 (56.5 %) 22 (13.8 %) 83 (31.1 %) 0.161
Normal WHR (0.96–1.0, M; 0.81–0.85, F) 14 (13 %) 29 (18.2 %) 43 (16.1 %)
High (WHR >1.0, M; >0.85, F 33 (30.6 %) 108 (67.9 %) 141 (52.8 %)
Days after Dose 1
Median (Range)
360 (63–420) 270 (58–420) 360 (180–401) 0.025
Days after Dose 2
Median (Range)
270 (58–395) 210 (13–395) 300 (120–395) 0.05
Vaccine Dose 3 Status 38 (33.9 %) 49 (28,5 %) 90 (31.7 %) 0.51
Days after Dose 3
Median (Range)
49 (2–89) 60 (2–150) 52.5 (1–115) 0.02
RT-PCR positivity 97 (89.8 %) 129 (81.1 %) 226 (84.6 %) 0.76
Need for Hospitalization 27 (25 %) 32 (20.1 %) 59 (22.1 %) 0.37
Need for supplementary oxygen 6 (5.6 %) 11 (6.9 %) 17 (6.4 %) 0.80
Comorbidity 34 (31.5 %) 59 (37.1 %) 93 (34.8 %) 0.36

Data were expressed as number (percentage) [n (%)] or median (range) as appropriate. Chi-square and Mann-Whitney tests were used to find out the association between categorical and continuous variables, respectively. P < 0.05 was considered as significant. BMI, Body Mass Index; WHR, Waist-Hip Ratio.